Matches in Nanopublications for { ?s ?p "[These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensitized to cisplatin therapy by the selective wee-1 kinase inhibitor, supporting the clinical evaluation of MK-1775 in combination with cisplatin for the treatment of patients with TP53 mutant HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensitized to cisplatin therapy by the selective wee-1 kinase inhibitor, supporting the clinical evaluation of MK-1775 in combination with cisplatin for the treatment of patients with TP53 mutant HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensitized to cisplatin therapy by the selective wee-1 kinase inhibitor, supporting the clinical evaluation of MK-1775 in combination with cisplatin for the treatment of patients with TP53 mutant HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion description "[These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensitized to cisplatin therapy by the selective wee-1 kinase inhibitor, supporting the clinical evaluation of MK-1775 in combination with cisplatin for the treatment of patients with TP53 mutant HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_provenance.
- NP1248056.RAEBZalglbsbM-18gb6MhyGUzY_u_rqAJtCDIMYgBWFI0130_assertion description "[These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensitized to cisplatin therapy by the selective wee-1 kinase inhibitor, supporting the clinical evaluation of MK-1775 in combination with cisplatin for the treatment of patients with TP53 mutant HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248056.RAEBZalglbsbM-18gb6MhyGUzY_u_rqAJtCDIMYgBWFI0130_provenance.